Document is current

Article History

Received: 16 October 2025

Accepted: 17 December 2025

First Online: 9 January 2026

Declarations

:

: All data used in the study consisted of aggregated and anonymized secondary data acquired with the approval of the data owner. As a result, approval from an Institutional Review Board or independent ethics committee was not required [ ]. The study was conducted in accordance with the principles of the Declaration of Helsinki, where applicable. The study was carried out in accordance with the appropriate legislation in Finland, and the study was conducted by the provision of the Act on the Secondary Use of Health and Social Data (Finland’s Ministry of Justice 552/2019); therefore, no informed consent from the patients was required. The study complied with legal and regulatory standards, adhering to the International Epidemiological Association’s Good Epidemiological Practice guidelines to ensure scientific value and rigor.

: Not applicable.

: Caihua Liang, Mikko Kosunen, Olli-Pekka Hätinen, Bradford D. Gessner, and Elizabeth Begier are employees of Pfizer and may own Pfizer stock. Robin Bruyndonckx, Aleksandra Polkowska-Kramek, Mikel Esnaola, Maribel Casas, Worku Biyadgie Ewnetu, and Pimnara Peerawaranun are employees of P95, which received funding from Pfizer in connection with the development of this manuscript and to conduct this study.